A cellular model to study drug-induced liver injury in nonalcoholic fatty liver disease: Application to acetaminophen
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Obesity and nonalcoholic fatty liver disease (NAFLD) can increase susceptibility to hepatotoxicity induced by some xenobiotics including drugs, but the involved mechanisms are poorly understood. For acetaminophen (APAP), a role of hepatic cytochrome P450 2E1 (CYP2E1) is suspected since the activity of this enzyme is consistently enhanced during NAFLD. The first aim of our study was to set up a cellular model of NAFLD characterized not only by triglyceride accumulation but also by higher CYP2E1 activity. To this end, human HepaRG cells were incubated for one week with stearic acid or oleic acid, in the presence of different concentrations of insulin. Although cellular triglycerides and the expression of lipid-responsive genes were similar with both fatty acids, CYP2E1 activity was significantly increased only by stearic acid. CYP2E1 activity was reduced by insulin and this effect was reproduced in cultured primary human hepatocytes. Next, APAP cytotoxicity was assessed in HepaRG cells with or without lipid accretion and CYP2E1 induction. Experiments with a large range of APAP concentrations showed that the loss of ATP and glutathione was almost always greater in the presence of stearic acid. In cells pretreated with the CYP2E1 inhibitor chlormethiazole, recovery of ATP was significantly higher in the presence of stearate with low (2.5 mM) or high (20 mM) concentrations of APAP. Levels of APAP-glucuronide were significantly enhanced by insulin. Hence, HepaRG cells can be used as a valuable model of NAFLD to unveil important metabolic and hormonal factors which can increase susceptibility to drug-induced hepatotoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Martignoni, M., Groothuis, G. M. M., & de Kanter, R. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.6.875 · Cited by 1,478 · cited 2×
“, 2005a), there are numerous differences between rodents and humans regarding hepatic drug metabolism (Chu et al., 2013; Martignoni et al., 2006).”
BackgroundMechanisms of Acetaminophen-Induced Liver Necrosis
Hinson, J. A., Roberts, D. W., & James, L. P. (2010) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-00663-0_12 · Cited by 1,006
Michelotti, G. A., Machado, M. V., & Diehl, A. M. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.183 · Cited by 974
Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease
Begriche, K., Massart, J., Robin, M.-A., Bonnet, F., & Fromenty, B. (2013) · Hepatology · doi:10.1002/hep.26226 · Cited by 628
Self-citationA feed-forward loop amplifies nutritional regulation of PNPLA3
Huang, Y., He, S., Li, J. Z., Seo, Y.-K., Osborne, T. F., Cohen, J. C., & Hobbs, H. H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003585107 · Cited by 386 · cited 1×
“2), in keeping with previous studies (Dubuquoy et al., 2011; Huang et al., 2010).”
Molecular Basis of Electrophilic and Oxidative Defense: Promises and Perils of Nrf2
Ma, Q., & He, X. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.004333 · Cited by 317 · cited 1×
“Importantly, nuclear factor, erythroid 2-like 2 (NRF2, or NFE2L2) is a transcription factor playing a major role in the regulation of most of these genes (Chan et al., 2001; Ma and He, 2012).”
BackgroundLake, A. D., Novak, P., Fisher, C. D., Jackson, J. P., Hardwick, R. N., Billheimer, D. D., Klimecki, W. T., & Cherrington, N. J. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040592 · Cited by 167 · cited 3×
“NAFLD is often associated with obesity and type 2 diabetes and encompasses a large spectrum of liver lesions including fatty liver, nonalcoholic steatohepatitis (NASH) and cirrhosis (Michelotti et al., 2013).”
BackgroundNguyen, G. C., Sam, J., & Thuluvath, P. J. (2008) · Hepatology · doi:10.1002/hep.22536 · Cited by 107 · cited 4×
“Although some investigations reported that patients with NAFLD had an overall higher risk of severe APAP-induced liver injury (Myers and Shaheen, 2008; NGuyen et al., 2008), such risk may actually vary from one obese individual to another.”
BackgroundInfluentialMyers, R. P., & Shaheen, A. A. M. (2009) · Hepatology · doi:10.1002/hep.22798 · Cited by 36 · cited 1×
“…model of human NAFLD which can be a valuable tool to gain insight regarding the mechanisms whereby this frequent hepatic disease appears to favor APAP-induced acute liver failure in some patients, in particular after an overdose (Michaut et al., 2014; Myers and Shaheen, 2009; NGuyen et al., 2008).”
Background
Cited by
High-Fidelity Drug-Induced Liver Injury Screen Using Human Pluripotent Stem Cell–Derived Organoids
Shinozawa, T., Kimura, M., Cai, Y., Saiki, N., Yoneyama, Y., Ouchi, R., Koike, H., Maezawa, M., Zhang, R.-R., Dunn, A., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.10.002 · Cited by 378
Human in vitro models of nonalcoholic fatty liver disease
Müller, F. A., & Sturla, S. J. (2019) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2019.03.001 · Cited by 118
Rafiei, H., Yeung, M., Kowalski, S., Krystal, G., & Elisia, I. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1234300 · Cited by 21
Metadata
- Authors
- Michaut, A., Le Guillou, D., Moreau, C., Bucher, S., McGill, M. R., Martinais, S., Gicquel, T., Morel, I., Robin, M.-A., Jaeschke, H., & Fromenty, B.
- Venue
- Toxicology and Applied Pharmacology
- Publisher
- Elsevier BV
- Published
- 2016-02
- Volume
- 292
- Pages
- 40-55
- ISSN
- 0041-008X (ISSN-L)
- OpenAlex
- W2205462610
- Cited by
- 73
- References
- 9
- FWCI
- 8.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A cellular model to study drug-induced liver injury in nonalcoholic fatty liver disease: Application to acetaminophen. https://app.cochat.ai/papers/10.1016/j.taap.2015.12.020
- The paper
- Michaut, A., Le Guillou, D., Moreau, C., Bucher, S., McGill, M. R., Martinais, S., Gicquel, T., Morel, I., Robin, M.-A., Jaeschke, H., & Fromenty, B. (2016). A cellular model to study drug-induced liver injury in nonalcoholic fatty liver disease: Application to acetaminophen. Toxicology and Applied Pharmacology. https://doi.org/10.1016/j.taap.2015.12.020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.